ライフサイエンスコーパス: valerate

1 were observed with alpha-keto-beta-methyl-n-valerate.

2 thin the community enabled the production of valerate (0.61 g L(-1)) and pentanol (0.33 g L(-1)), whi

3 FHT (E2 valerate 2 mg/d and cyproterone acetate 25 mg/d) was pre

4 etween diets (acetate, propionate, butyrate, valerate, 3-phenylopropionate, and 2-hydroxyvalerate).

5 ate (21.9%, 95% CI 6.99 to 38.9, p = 0.003), valerate (35.7%, 95% CI 4.53 to 76.2, p = 0.02), and alp

6 In artificial cycles, oral oestradiol valerate (8 mg/day from day 2-4 of menstruation) and vag

7 F-kappaB activation by N-benzyladriamycin-14-valerate (AD 198) and N-benzyladriamycin-14-pivalate (AD

8 N-Benzyladriamycin-14-valerate (AD 198) is a semisynthetic anthracycline with

9 targeted anthracycline N-benzyladriamycin-14-valerate (AD198), a PKC-delta activator, to investigate

10 s transamination between alpha-ketoiso[1-14C]valerate and L-isoleucine.

11 Propionate, butyrate, valerate, and caproate induced severalfold increases in

12 roduction of propionate, trans-2-pentenoate, valerate, and pentanol, compounds with applications that

13 tation of Ctrl feces increased the butyrate, valerate, and propionate levels in cecal content of SCD

14 ns despite its ability to use propionate and valerate as carbon sources.

15 s (SCFAs) acetate, propionate, butyrate, and valerate, as well as the branched-chain fatty acids (BCF

16 We recently showed that betamethasone valerate (BM) although clinically more efficient impaire

17 st, the in vitro release of betamethasone-17-valerate (BMV), a representative dermatological drug, wa

18 Unlike betamethasone valerate (BMV), long-term NF-kappaB Decoy treatment does

19 In reporter gene assays, propionate, valerate, caproate, and also octanoate increased Glc-6-P

20 th the top and bottom 33% of butyrate or iso/valerate concentrations prior to radiotherapy revealed 1

21 lic esters with optimal activity towards the valerate ester.

22 (-1)), which can effectively catalyze pentyl valerate esterification and be easily separated by an ex

23 OS contributors in a rat model of estradiol valerate (EV)-induced PCOS.

24 z)](3+) [bpy' = 4-(4'-methyl-2, 2'-bipyridyl)valerate], generated in situ by flash-quench methodology

25 00 microg, or 400 microg, or oral oestradiol valerate in doses of 1 mg or 2 mg, daily for 12 weeks.

26 pK(is) profile for the competitive inhibitor valerate, indicating that nitroethane has no significant

27 aecal SCFAs, including butyrate, propionate, valerate, isovalerate, and hexanoate after RS4-intake.

28 ic the conformation proposed for the natural valerate linker, possessed DNA cleavage activity, albeit

29 s of conformational constraint of the native valerate moiety.

30 opsis taxiformis also increased butyrate and valerate molar proportions by 7 and 24%, respectively, w

31 alone and in combination with betamethasone valerate ointment, in the NC/Nga mouse model of mite-ind

32 The animals received beta-estradiol 17-valerate once a week and were treated daily with the sel

33 re treated with 100 mug/kg beta-estradiol 17-valerate or vehicle (control) over 7 and 28 days.

34 A similar relationship was observed for iso/valerate (p = 0.025).

35 propionate (p = 0.02), butyrate (p = 0.03), valerate (p = 0.03), and alpha-methylbutyrate (p = 0.02)

36 In this regard, the carbonyl of the 14-valerate participates in hydrogen bonding to the deltaC1

37 trate-rich diet showed increases in alanine, valerate, propionate, glucose, tyrosine, proline and iso

38 The competitive inhibitor valerate protects the enzyme from inactivation by tetran

39 The competitive inhibitor valerate protects the enzyme from inactivation, indicati

40 an those values for alpha-keto-beta-methyl-n-valerate, respectively.

41 Betamethasone valerate resulted in a significant reduction in mRNA lev

42 anitromethane in the presence and absence of valerate shows a single peptide differentially labeled i

43 4)C]maleimide in the absence and presence of valerate shows a single radioactive peptide differential

44 data demonstrating the importance of the 14-valerate side chain of AD 198 in binding to the C1 domai

45 of PKC-alpha to the membrane requires the 14-valerate substituent.

46 here in mouse brain by replacing the phenyl valerate substrate of the standard NTE assay with lysole

47 from acetate to butyrate (beta = +6.96) and valerate to heptanoate (beta = +0.85).

48 the basis of measured sensitivities, phenyl valerate was the preferred substrate for NEST and BChE,

49 pH-independent when alpha-keto-beta-methyl-n-valerate was used as the ketoacid substrate.